Ida Tin

Who they are

Ida Tin is Chairwoman of Clue and founder of FemTech Assembly — the Danish entrepreneur who coined the term 'FemTech' and led Clue from its 2012 founding to 11 million monthly active users and the world's first all-digital FDA-approved birth control.

Person

Ida Tin trained at KaosPilots in Denmark — a BA-level school in social entrepreneurship — and studied art in South Africa and London before any of her companies existed. Before founding Clue, she co-founded MotoMundo with her father, running guided motorcycle tours through Mongolia, Cuba, and Vietnam, and published 'Directress' (Direktøs) in 2009, a memoir of a solo motorcycle ride across the western United States. In 2012 she founded Clue (BioWink GmbH) in Berlin, built it to 11 million monthly active users, steered it through the 2021 FDA clearance that made it the first all-digital approved birth control, then stepped back from the CEO role in March 2021 when Audrey Tsang and Carrie Walter took over as co-CEOs — she stayed on as Chairwoman. Alongside Clue she founded FemTech Assembly, a think tank connecting women's health investment to economic and planetary goals, and is now leading a €40 million initiative at SPRIND (Germany's federal innovation agency) focused on biosensors for continuous hormone monitoring in women. She coined the term 'FemTech' and is its most visible public advocate — writing on LinkedIn and the FemTech Assembly Substack about hormonal data, data privacy, and investment in women's health, speaking at Slush, TechCrunch Disrupt, TEDx, Web Summit, HIMSS Europe, and Tatra Summit 2024, and is a Fast Company 100 Most Creative People alum from 2016. She is working on a book about FemTech and is active enough on the circuit to be listed on the AAE Speakers Bureau. Possibly — her current primary institutional home is SPRIND, given recent podcast appearances there in 2025–2026.

Company

FemTech Assembly is the think tank Ida Tin founded to make the case that investing in women's health is a path to economic growth — it publishes via Substack and convenes stakeholders across industry, policy, and capital. The sharpest signal of Ida's current focus is the €40 million SPRIND initiative she is leading on biosensors for continuous hormone monitoring in women — a hardware-layer bet that the data infrastructure for women's health barely exists yet. Flo Health's 2024 unicorn round ($200 million) and Natural Cycles' $55 million raise in May 2024 validate the sector's momentum, giving FemTech Assembly a more favorable funding climate to work in. The menopause category — the fastest-growing in femtech, with $294 million raised across 19 deals — is also a natural area for the think tank's advocacy work.

Market

The femtech market is attracting serious capital: Flo Health hit unicorn status in 2024, Maven Clinic raised $125 million in October 2024 at a $1.7 billion valuation, and Redesign Health launched a $175 million fund in December 2024 for the next wave of ventures. Competitors range from digital-native platforms like Clue, Flo, and Maven Clinic to pharma and CPG incumbents including Bayer and Procter & Gamble, with LifeMD entering via acquisition in 2025. Regulatory headwinds — post-Roe uncertainty, the EU AI Act delaying CE certifications, and racial bias in AI training data — sit alongside tailwinds like EMA's 2024 acceptance of synthetic clinical data, creating an uneven but clearly expanding field.

Network

Ida's closest named professional connections are Audrey Tsang and Carrie Walter, the co-CEOs who succeeded her at Clue in March 2021 and with whom she presumably still has a board relationship as Chairwoman. Her SPRIND initiative places her in the orbit of Germany's federal innovation ecosystem. No additional named edges are available from the claims.

Audrey Tsang· Co-CEO, Clue
Carrie Walter· Co-CEO, Clue

How they likely show up

Founded Clue in 2012 and stayed through March 2021 as CEO — nearly a decade of operator tenure before moving to Chairwoman — suggests she thinks in long build cycles, not quick exits.
Coined a term that named an entire industry ('FemTech') → she operates at the level of framing and narrative, not just product execution.
MotoMundo, FemTech Assembly, the SPRIND biosensor initiative, and a book in progress alongside Clue chairmanship → high agency, runs multiple bets in parallel, likely impatient with single-track thinking.
Active LinkedIn poster and FemTech Assembly Substack writer on hormonal data and investment themes → comfortable being a public voice, expects interlocutors to have read the work.
Moved from CEO to Chairwoman voluntarily and handed off operations to co-CEOs → values the mission over the title; probably more interested in systemic change than in day-to-day management.
Published a travel memoir in 2009 and is writing a FemTech book now → narrative thinking is core to how she processes and communicates ideas.

Conversation tips

→ Reference a specific FemTech Assembly Substack post or a LinkedIn piece she wrote — she'll clock immediately whether you've actually read her work.
→ The SPRIND biosensor initiative is the sharpest current thread; ask about it specifically rather than asking generally about 'what's next in femtech.'
→ She distinguishes between companies building products and people trying to reshape the infrastructure of an entire field — make clear which conversation you're there to have.
→ Don't conflate FemTech Assembly with Clue; they're separate organizations with different mandates and she is precise about that distinction.
→ Her background is in social entrepreneurship, not engineering — frame technical or data topics in terms of what they unlock for women, not in terms of technical specs.

Toolbox

Openers

Open on the SPRIND biosensor initiative — she's leading a €40 million program to build continuous hormone monitoring hardware, which is a very specific infrastructure bet that most people in femtech aren't making yet.
Mention FemTech Assembly's Substack — she publishes there on investment, hormonal data, and planetary well-being framing, and naming her own publication signals you've done more than a LinkedIn skim.
Ask about the Flo data privacy episode she commented on publicly — she posted about Flo's data practices and her own shortcomings in that space, which opens a sharp conversation about what responsible data stewardship actually looks like in women's health.

Discovery questions

The SPRIND biosensor initiative is a hardware bet on women's hormone data infrastructure — what's the gap in the sensing layer that made that the right next move over purely software approaches?
You stepped back from the Clue CEO role in 2021 after nearly a decade — what does being Chairwoman let you do that being CEO didn't, and how do you think about that transition now?
FemTech Assembly frames women's health investment as a path to economic growth and planetary well-being — what's the argument you're still having to make to get institutional capital to see it that way?

Avoid

Don't treat 'FemTech' as a niche or emerging category she's evangelizing — she coined the term over a decade ago and has spent that time building real infrastructure; framing it as nascent or speculative will read as uninformed.

Make it yours